Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI) Stock Price, Quote & AI Analysis

Live MRVI stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Maravai LifeSciences Holdings, Inc. Class A Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

MRVI
Maravai LifeSciences Holdings, Inc. Class A Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
3.000000
High
3.195000
Low
3.000000
Volume
1,850,440
VWAP
-
Market Cap
$495,977,808.42
52W Range
$1.67 - $4.11
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
May 11, 2026 Q1
After Hours
EPS Estimate: $-0.0584
Revenue Estimate: $51,771,936.00
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Maravai LifeSciences Holdings, Inc. Class A Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Maravai LifeSciences Holdings, Inc. Class A Common Stock Overview

Company information

Company Overview

Maravai Lifesciences Holdings, Inc. engages in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm’s brands include TriLink BioTechnologies, Cygnus, Glen Research, and Alphazyme. It operates through the TriLink and Cygnus segments. The TriLink segment manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Cygnus segment sells biologic safety testing products and highly specialized analytical products for use in biologic manufacturing process development, including custom product-specific antibody and assay development services. It also operates through the following geographical segments: North America, Asia Pacific, Europe, the Middle East, and Africa, and Latin and Central America. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

Company Details
Market Cap
$799.48M
Shares Outstanding
257,067,173
Weighted Shares Outstanding
145,022,751
CEO
Bernd Brust
Address
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO, CA, 92121
Employees
550
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Maravai LifeSciences Holdings, Inc. Class A Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...